Skip to main content

Table 3 Incidence of adverse events that caused discontinuation of treatment

From: The effectiveness of retreatment with peginterferon alfa and ribavirin in patients with chronic viral hepatitis C genotype 2 and 3: a prospective cohort study in Brazil

Adverse events (n = 40) Incidence of occurrence, n (%)
Laboratory abnormality 16 (40)
Descompensated cirrhosis (ascites/encephalopathy) 7 (17.5)
Incapacitating symptoms 4 (10)
Acute Renal Failure 3 (7.5)
Psoriasis 1 (2.5)
Diagnosis of Hepatocellular carcinoma 1 (2.5)
Death 8 (20)